VK 2019

VK-2019 EBNA1 inhibitor · Stanford University

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for VK 2019, covering 2023-08-15 to 2025-10-21. Get the full timeline:

Most recent: Clinical Trial Update: Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus (EBV)-Positive Nasopharyngeal Cancer (NPC) and Other Epstein-Barr Virus (EBV)-Associated Cancers, With Pharmacokinetic and Pharmacodynamic Correlative Studies [Phase 2]

See pricing